Abstract
Tumor mutational signatures are informative for cancer diagnosis and treatment. However, targeted sequencing, commonly used in clinical settings, lacks specialized analytical tools and a dedicated catalogue of mutational signatures. Here, we introduce SATS, a scalable mutational signature analyzer for targeted sequencing data. SATS leverages tumor mutational burdens to identify and quantify signatures in individual tumors, overcoming the challenges of sparse mutations and variable gene panels. Validations across simulated data, pseudo-targeted sequencing data, and matched whole-genome and targeted sequencing samples show that SATS can accurately detect common mutational signatures and estimate their burdens. Applying SATS to 111,711 tumors from the AACR Project GENIE, we created a pan-cancer mutational signature catalogue specific to targeted sequencing. We further validated signatures in lung, breast and colorectal cancers using an additional 16,774 independent samples. This signature catalogue is a valuable resource for estimating signature burdens in individual targeted sequenced tumors, facilitating the integration of mutational signatures with clinical data.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was conducted with support from Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics (DCEG). Additionally, Dr. Lee was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT, No. RS-2023-00213625).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at https://synapse.org/genie, https://cancer.sanger.ac.uk/signatures/, https://gdc.cancer.gov/about-data/publications/mc3-2017, ftp://ftp.sanger.ac.uk/pub/cancer/Nik-ZainalEtAl-560BreastGenomes, https://www.synapse.org/#!Synapse:syn26706790, https://www.synapse.org/#!Synapse:syn11726618, and https://www.synapse.org/#!Synapse:syn11801497.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This version of the manuscript has been revised to update the following: The entire manuscript is revised for further clarification; Section for validation with independent cohort is newly included; Main Figures 1, 5, 6 are revised according to the manuscript; and Supplementary figures, tables, and notes are also updated accordingly.
Data Availability
The AACR Project GENIE dataset could be retrieved from Synapse (https://synapse.org/genie)
